One of the biggest mergers of the year, worth $49 billion, comes just weeks after the Trump administration linked the common painkiller to autism, which the company is fighting.

Tylenol faces scrutiny over pregnancy use and autism links, despite scientific bodies finding no firm evidence. While observational studies show weak associations, many experts warn against unwarranted fear.

The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.

Not long after President Trump made his statement, Kenvue and Johnson & Johnson got into another complicated legal mess when the Republican state of Texas sued them. The complaint says that the companies didn’t tell people about the possible risks of taking acetaminophen while pregnant.

Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company.

Most Utah voters have heard that the Trump administration's claim that acetaminophen use during pregnancy is linked to autism, but far fewer actually believe that claim.

Tylenol maker Kenvue said Texas' claims "lack legal merit and scientific support" and vowed to defend itself in litigation.

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.

Kimberly-Clark is buying Kenvue, the maker of Tylenol, after months of controversy around whether the medicine is linked to autism.

Even though Kenvue's stock was already in a tailspin before the FDA warned pregnant woman that Tylenol posed a health risk, there are still some lingering impacts to consider.